Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (1171)	1/17/2001 2:14:40 PM
From: Madharry	Respond to of 1386

I do not know how they conducted the trials . I would like to be convinced that this is not a potential problem. so far nothing you have said has convinced me. but that would be part of my due dilligence before investing.

To: wolfdog2 who wrote (1171)	1/17/2001 9:28:17 PM
From: Madharry	Read Replies (3) \| Respond to of 1386

Also - and I certainly have no practical experience in this but the difficulty in finding subjects seems to be born out by the fact that they plan to use 70 centers to find 860 patients. Is this not a pretty unusual way to do a study? Do they get some sort of prior approval from the fda for the framework of their study? I would think it might be difficult to get everybody on the same page. I have no position and would like both the company and its investors to be successful. but I just want to more aware of potential problems. If there are any drug researchers reading with practical experience on phase III. please enlighten me.